Trial Profile
Mechanisms of Vascular Dysfunction in Women: Role of Estradiol
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Nov 2022
Price :
$35
*
At a glance
- Drugs Estradiol (Primary) ; Ganirelix
- Indications Atrophic vaginitis; Menopausal syndrome; Postmenopausal osteoporosis; Primary ovarian insufficiency; Vasomotor symptoms
- Focus Pharmacodynamics
- 10 Nov 2022 Status changed from recruiting to completed.
- 16 Oct 2021 retained status as per NCT (updated on 15 Oct 2021) ,though as per result it is given 15 pts completed the study (1 Sep 2021) ,Also full text of article is of accessible.Pls update further as and when more info will be available on this.
- 14 Oct 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2022.